Georgina Long, MBBS, PhD, FRACP, discusses unmet needs for BRAF-mutant melanoma, highlighting key insights from the phase 3 NADINA trial.
Georgina Long, BSc, PhD, MBBS, FRACP
Advertisement
Articles by Georgina Long, BSc, PhD, MBBS, FRACP
Georgina Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600–mutant melanoma.
Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses which patients may benefit from the combination of dabrafenib and trametinib based on several recent clinical trials.
Advertisement
Latest Updated Articles
Dr. Georgina Long on Dabrafenib and Trametinib in BRAF-Mutated MelanomaPublished: November 21st 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5